Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

BPH (Benign Prostatic Hyperplasia): early-phase trial registry

1 of 3 indexed BPH (Benign Prostatic Hyperplasia) trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #5,209 of 28,707 conditions by registered trial count.

3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count

BPH (Benign Prostatic Hyperplasia): 3 US clinical trials tracked, 1 recruiting.

BPH (Benign Prostatic Hyperplasia) is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Butterfly Medical, running 1 of these trials.

Enrollment posture brief

Registry condition bph-benign-prostatic-hyperplasia

OPEN 1 | RECR 33% | LATE 0 | EARLY 1 | RANK #5209 | SPON 1

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%BPH (this)33%
Open-enrollment share among volume-matched conditions near BPH (Benign Prostatic Hyperplasia)

BPH (Benign Prostatic Hyperplasia) lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for BPH (Benign Prostatic Hyperplasia) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. BPH (Benign Prostatic Hyperplasia) is recruiting below its size-band peers.

    1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Top Sponsors

Named interventions

Most-linked intervention names on BPH (Benign Prostatic Hyperplasia) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Butterfly Prostatic Retraction Device Device
1 trials
Zenflow Spring System Device
1 trials
Sham Procedure Device
1 trials
Finasteride Drug
1 trials
raloxifene Drug
1 trials

US sites by state

Facility locations filed on BPH (Benign Prostatic Hyperplasia) trials. A trial with sites in several states counts in each.

Texas 2 trials
Virginia 1 trials
South Carolina 1 trials
New York 1 trials
Nevada 1 trials
Massachusetts 1 trials
Illinois 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this BPH (Benign Prostatic Hyperplasia) page

3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 BPH (Benign Prostatic Hyperplasia) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Butterfly Medical sponsors the most BPH (Benign Prostatic Hyperplasia) trials on record, review their full trial history before evaluating a specific study. See Butterfly Medical's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This BPH (Benign Prostatic Hyperplasia) condition card totals 3 registered trials; most-linked intervention Butterfly Prostatic Retraction Device; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.